Page last updated: 2024-08-02 07:22:32

tri-cyclen

Description

Cross-References

ID Source	ID
PubMed CID	9571023
SCHEMBL ID	6382955
MeSH ID	M0283176

Synonyms (37)

Synonym
ortho cyclen-28
ortho tri-cyclen
ortho cyclen-21
tri-sprintec
tricileste
norgestimate, ethinyl estradiol drug combination
pramino
ethinylestradiol-norgestimate mixt
estarylla
ortho tri-cyclen 28
norgestimate-ethinylestradiol mixt
tri-lo-sprintec
ortho cylen
tri-mili
trinessa
ortho tri lo
ortho tri cyclen
tri-linyah
mono-linyah
mili
ortho tri-cyclen lo
norgestimate and ethinyl estradiol
tri-estarylla
tri cyclen
mononessa
tri-lo-estarylla
ortho tri-cylen
79871-54-8
tri prevofem
norgestimate / ethinyl estradiol
ortho tri-cyclen 21
ethinyl estradiol and norgestimate
trinessa-28
18,19-dinorpregn-4-en-20-yn-3-one, 17-(acetyloxy)-13-ethyl-, 3-oxime, (17alpha)-, mixt. with (17alpha)-19 norpregna-1,3,5(10)-trien-20-yne-3,17-diol
tricilest
SCHEMBL6382955
[(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol

Research

Studies (49)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.04)	18.7374
1990's	17 (34.69)	18.2507
2000's	15 (30.61)	29.6817
2010's	16 (32.65)	24.3611
2020's	0 (0.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	32 (59.26%)	5.53%
Reviews	7 (12.96%)	6.00%
Case Studies	3 (5.56%)	4.05%
Observational	1 (1.85%)	0.25%
Other	11 (20.37%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's
adenine	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2009	2009	15.0	low	1	0	0	1	0
carbamates	1	amino-acid anion		2014	2014	10.0	low	1	0	0	0	1
caffeine	1	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic	2005	2005	19.0	low	1	0	0	1	0
metformin	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic	2011	2011	13.0	low	1	0	0	0	1
midazolam	1	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative	2005	2005	19.0	low	1	0	0	1	0
omeprazole	1	aromatic ether; benzimidazoles; pyridines; sulfoxide		2005	2005	19.0	low	1	0	0	1	0
methacetin	1	acetamides; aromatic ether		2013	2013	11.0	low	0	0	0	0	1
androsterone	1	17-oxo steroid; 3alpha-hydroxy steroid; androstanoid; C19-steroid	androgen; anticonvulsant; human blood serum metabolite; human metabolite; human urinary metabolite; mouse metabolite; pheromone	2002	2002	22.0	low	1	0	0	1	0
dehydroepiandrosterone	1	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite	1996	1996	28.0	low	1	0	1	0	0
ethinyl estradiol	49	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen	1986	2019	20.3	high	31	1	17	17	14
uridine monophosphate	1	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite	2014	2014	10.0	low	0	0	0	0	1
androstenedione	2	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite	1996	2010	21.0	low	1	0	1	1	0
norethindrone	3	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive	2001	2009	18.7	low	2	0	0	3	0
17-alpha-hydroxyprogesterone	1	17alpha-hydroxy-C21-steroid; 17alpha-hydroxy steroid; tertiary alpha-hydroxy ketone	human metabolite; metabolite; mouse metabolite; progestin	1996	1996	28.0	low	1	0	1	0	0
valine	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite	2014	2014	10.0	low	1	0	0	0	1
adamantane	1	adamantanes; polycyclic alkane		2012	2012	12.0	low	1	0	0	0	1
isoxazoles	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene		2005	2005	19.0	low	0	0	0	1	0
cyproterone acetate	1	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; chlorinated steroid; steroid ester	androgen antagonist; geroprotector; progestin	2013	2013	11.0	low	0	0	0	0	1
nandrolone	1	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid	human metabolite	2013	2013	11.0	low	1	0	0	0	1
dihydrotestosterone	1	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite	1996	1996	28.0	low	1	0	1	0	0
dehydroepiandrosterone sulfate	2	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite	1996	2002	25.0	low	2	0	1	1	0
levonorgestrel	2	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive	2005	2013	15.0	low	1	0	0	1	1
ethinyl estradiol-norgestrel combination	20			1986	2013	27.4	medium	10	1	14	4	1
desogestrel	6	17beta-hydroxy steroid; terminal acetylenic compound	contraceptive drug; progestin; synthetic oral contraceptive	1996	2013	23.0	low	4	0	4	1	1
atorvastatin	1	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic	2016	2016	8.0	low	1	0	0	0	1
dt 5061	3			2001	2009	18.7	low	2	0	0	3	0
ortho-cept	2			1999	2013	18.0	low	1	0	1	0	1
dexloxiglumide	1	glutamic acid derivative		2005	2005	19.0	low	1	0	0	1	0
shd 415g	3			1996	1998	27.0	medium	3	0	3	0	0
drospirenone	2	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin	2004	2009	17.5	low	2	0	0	2	0
cyproterone acetate, ethinyl estradiol drug combination	1			2013	2013	11.0	low	0	0	0	0	1
androsterone glucuronide	1	beta-D-glucosiduronic acid; steroid glucosiduronic acid	human metabolite; metabolite; mouse metabolite	2002	2002	22.0	low	1	0	0	1	0
valdecoxib	1	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2005	2005	19.0	low	0	0	0	1	0
drospirenone and ethinyl estradiol combination	2			2010	2013	12.5	low	0	0	0	1	1
atazanavir sulfate	1	organic sulfate salt		2011	2011	13.0	low	0	0	0	0	1
organophosphonates	1	divalent inorganic anion; phosphite ion		2009	2009	15.0	low	1	0	0	1	0
dacuronium	1			1996	1996	28.0	low	1	0	1	0	0
ritonavir	1	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic	2011	2011	13.0	low	0	0	0	0	1
pancuronium	1	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist	1996	1996	28.0	low	1	0	1	0	0
tretinoin	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule	2011	2011	13.0	low	1	0	0	0	1
alitretinoin	1	retinoic acid	antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist	2011	2011	13.0	low	1	0	0	0	1
tenofovir	1	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor	2009	2009	15.0	low	1	0	0	1	0
dimethyl fumarate	1	diester; enoate ester; methyl ester	antipsoriatic; immunomodulator	2017	2017	7.0	low	1	0	0	0	1
citraconic acid	1	dicarboxylic acid; dicarboxylic fatty acid	human metabolite	2017	2017	7.0	low	1	0	0	0	1
gestodene	1	steroid	estrogen	2013	2013	11.0	low	0	0	0	0	1
vitamin k semiquinone radical	1			2005	2005	19.0	low	1	0	0	1	0
dextromethorphan	1	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic	2005	2005	19.0	low	1	0	0	1	0
fumarates	1	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite	2017	2017	7.0	low	1	0	0	0	1
bms201038	1	(trifluoromethyl)benzenes; benzamides; fluorenes; piperidines	anticholesteremic drug; MTP inhibitor	2016	2016	8.0	low	1	0	0	0	1
estradiol valerate-dienogest	1			2013	2013	11.0	low	1	0	0	0	1
norgestimate	6			1992	2011	26.0	low	3	0	4	1	1
norelgestromin	3			2005	2017	11.7	low	3	0	0	1	2
bms-790052	1	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	2014	2014	10.0	low	1	0	0	0	1
sofosbuvir	1	isopropyl ester; L-alanyl ester; nucleotide conjugate; organofluorine compound; phosphoramidate ester	antiviral drug; hepatitis C protease inhibitor; prodrug	2014	2014	10.0	low	0	0	0	0	1
warfarin	1	benzenes; hydroxycoumarin; methyl ketone		2005	2005	19.0	low	1	0	0	1	0
dolutegravir	1	difluorobenzene; monocarboxylic acid amide; organic heterotricyclic compound; secondary carboxamide	HIV-1 integrase inhibitor	2015	2015	9.0	low	1	0	0	0	1
ledipasvir	1	azaspiro compound; benzimidazole; bridged compound; carbamate ester; carboxamide; fluorenes; imidazoles; L-valine derivative; N-acylpyrrolidine; organofluorine compound	antiviral drug; hepatitis C protease inhibitor	2014	2014	10.0	low	0	0	0	0	1
norgestrel	49			1986	2019	20.3	high	31	1	17	17	14
allopurinol	1	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger	2005	2005	19.0	low	1	0	0	1	0

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	1990's	2000's	2010's
Acne	6	1992	2006	24.0	low	4	3	3	0
Acne Vulgaris	6	1992	2006	24.0	low	4	3	3	0
Bilateral Headache	3	1992	2013	23.3	low	2	2	0	1
Bleeding Between Periods	1	2009	2009	15.0	low	1	0	1	0
Complication, Postoperative	1	2012	2012	12.0	low	0	0	0	1
Complications, Pregnancy	1	2012	2012	12.0	low	0	0	0	1
Drug Withdrawal Symptoms	1	2013	2013	11.0	low	1	0	0	1
Embolism, Pulmonary	1	2005	2005	19.0	low	0	0	1	0
Endothelioma, Lymphatic	1	2012	2012	12.0	low	0	0	0	1
Facial Neoplasms	1	2012	2012	12.0	low	0	0	0	1
Headache	3	1992	2013	23.3	low	2	2	0	1
Hemorrhage, Uterine	4	1999	2009	20.5	low	3	1	3	0
Infections, Respiratory	1	1997	1997	27.0	low	1	1	0	0
Inflammation	1	2002	2002	22.0	low	1	0	1	0
Innate Inflammatory Response	1	2002	2002	22.0	low	1	0	1	0
Insulin Resistance	2	2011	2011	13.0	low	2	0	0	2
Insulin Sensitivity	2	2011	2011	13.0	low	2	0	0	2
Leanness	1	2011	2011	13.0	low	1	0	0	1
Lymphangioma	1	2012	2012	12.0	low	0	0	0	1
Lymphatic Abnormalities	1	2012	2012	12.0	low	0	0	0	1
Metrorrhagia	1	2009	2009	15.0	low	1	0	1	0
Nausea	3	1992	1999	28.0	low	2	3	0	0
Obesity	2	2011	2011	13.0	low	2	0	0	2
Overweight	1	2011	2011	13.0	low	1	0	0	1
Pelvic Pain	1	2013	2013	11.0	low	1	0	0	1
Polycystic Ovarian Syndrome	1	2011	2011	13.0	low	1	0	0	1
Polycystic Ovary Syndrome	1	2011	2011	13.0	low	1	0	0	1
Postoperative Complications	1	2012	2012	12.0	low	0	0	0	1
Pregnancy	7	1999	2012	20.4	medium	5	2	4	1
Pulmonary Embolism	1	2005	2005	19.0	low	0	0	1	0
Recrudescence	1	2012	2012	12.0	low	0	0	0	1
Respiratory Tract Infections	1	1997	1997	27.0	low	1	1	0	0
Substance Withdrawal Syndrome	1	2013	2013	11.0	low	1	0	0	1
Uterine Hemorrhage	4	1999	2009	20.5	low	3	1	3	0

Safety/Toxicity (3)

Article	Year
Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception, , Volume: 67, Issue:6	2003
Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception, , Volume: 60, Issue:6	1999
Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception, , Volume: 60, Issue:2	1999

Pharmacokinetics (10)

Article	Year
A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. CNS drugs, , Volume: 33, Issue:5	2019
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. Journal of clinical pharmacology, , Volume: 56, Issue:1	2016
Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. The Annals of pharmacotherapy, , Volume: 49, Issue:7	2015
Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. Journal of clinical pharmacology, , Volume: 54, Issue:11	2014
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antiviral therapy, , Volume: 19, Issue:5	2014
Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women. Diabetes, obesity & metabolism, , Volume: 14, Issue:12	2012
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antiviral therapy, , Volume: 16, Issue:2	2011
Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate. Clinical and experimental dermatology, , Volume: 36 Suppl 2	2011
Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy, , Volume: 29, Issue:8	2009
Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Journal of clinical pharmacology, , Volume: 45, Issue:3	2005

Dosage (7)

Article	Year
Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women. Clinical pharmacology in drug development, , Volume: 6, Issue:6	2017
Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. Journal of clinical pharmacology, , Volume: 56, Issue:1	2016
Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol. The Annals of pharmacotherapy, , Volume: 49, Issue:7	2015
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antiviral therapy, , Volume: 19, Issue:5	2014
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antiviral therapy, , Volume: 16, Issue:2	2011
Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy, , Volume: 29, Issue:8	2009
Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Journal of clinical pharmacology, , Volume: 45, Issue:3	2005

Interactions (2)

Article	Year
A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. CNS drugs, , Volume: 33, Issue:5	2019
Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women. Clinical pharmacology in drug development, , Volume: 6, Issue:6	2017

tri-cyclen

Description

Cross-References

Synonyms (37)

Research

Studies (49)

Study Types

Related Drugs (59)

Drugs Researched Together (59)

Related Conditions (34)

Safety/Toxicity (3)

Pharmacokinetics (10)

Dosage (7)

Interactions (2)